81682-38-4 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-5-chlorophenylacetic acid is utilized as an intermediate in the synthesis of various active pharmaceutical ingredients. Its role in the development of new drugs is significant, as it can be incorporated into the molecular structures of different medications to enhance their therapeutic effects.
Used in Organic Chemistry:
In the field of organic chemistry, 2-Bromo-5-chlorophenylacetic acid serves as a building block for the synthesis of complex organic molecules. Its unique structure allows chemists to use it as a starting material for creating a wide range of organic compounds with diverse applications.
Used in Biological Research:
2-Bromo-5-chlorophenylacetic acid has been studied for its potential biological activities, such as anti-inflammatory and anti-microbial properties. This makes it a valuable compound for research in the development of new treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 81682-38-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,6,8 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 81682-38:
(7*8)+(6*1)+(5*6)+(4*8)+(3*2)+(2*3)+(1*8)=144
144 % 10 = 4
So 81682-38-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H6BrClO2/c9-7-2-1-6(10)3-5(7)4-8(11)12/h1-3H,4H2,(H,11,12)
81682-38-4Relevant academic research and scientific papers
Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis
Chen, Lin-Hai,Fang, You-Chen,Nan, Fa-Jun,Xiao, Yu-Feng,Xie, Xin,Zhang, Qing
supporting information, p. 3991 - 4006 (2022/03/14)
GPR84 is a proinflammatory G protein-coupled receptor associated with several inflammatory and fibrotic diseases. GPR84 antagonists have been evaluated in clinical trials to treat ulcerative colitis, idiopathic pulmonary fibrosis, and nonalcoholic steatohepatitis. However, the variety of potent and selective GPR84 antagonists is still limited. Through high-throughput screening, a novel phosphodiester compound hit 1 was identified as a GPR84 antagonist. The subsequent structural optimization led to the identification of compound 33 with improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. In a DSS-induced mouse model of ulcerative colitis, compound 33 significantly alleviated colitis symptoms and reduced the disease activity index score at oral doses of 25 mg/kg qd, with an efficacy similar to that of positive control 5-aminosalicylic acid (200 mg/kg, qd, po), suggesting that compound 33 is a promising candidate for further drug development.
